Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carcinoembryonic antigen peptide 1-6D virus-like replicon particles vaccine

A cancer vaccine, consisting of alphavirus vector-derived virus-like replicon particles expressing the 9-amino-acid carcinoembryonic antigen peptide (CAP) 1-6D, with potential antineoplastic activity. Vaccination with this agent may elicit a cytotoxic T lymphocyte (CTL) immune response against CEA-expressing tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Abbreviation:	CEA(6D) VRP CEA(6D) VRP vaccine
Code name:	AVX701

carcinoembryonic antigen peptide 1-6D virus-like replicon particles vaccine

Search NCI's Drug Dictionary